Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.
| Revenue (Most Recent Fiscal Year) | $1.66M |
| Net Income (Most Recent Fiscal Year) | $-34.35M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 7.30 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -648.06% |
| Net Margin (Trailing 12 Months) | -665.19% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -124.15% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.87 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.87 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.62 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.06 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.47 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.37 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 78.51M |
| Free Float | 73.25M |
| Market Capitalization | $30.42M |
| Average Volume (Last 20 Days) | 0.51M |
| Beta (Past 60 Months) | 2.08 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 18.75% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |